292 results about "L lactide" patented technology

The present invention provides bioactive polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The composition can be used in an external wound dressing, as a polymer implant for delivery of the wound healing agent to an internal body site, or as a coating on the surface of an implantable surgical device to deliver wound healing agents that are covalently attached to a biocompatible, biodegradable polymer and/or embedded within a hydrogel. Methods of using the invention bioactive polymer compositions to promote natural healing of wounds, especially chronic wounds, are also provided. Examples of biodegradable copolymer polyesters useful in forming the blood-compatible, hydrophilic layer or coating include copolyester amides, copolyester urethanes, glycolide-lactide copolymers, glycolide-caprolactone copolymers, poly-3-hydroxy butyrate-valerate copolymers, and copolymers of the cyclic diester monomer, 3-(S)[(alkyloxycarbonyl)methyl]-1,4-dioxane-2,5-dione, with L-lactide. The glycolide-lactide copolymers include poly(glycolide-L-lactide) copolymers formed utilizing a monomer mole ratio of glycolic acid to L-lactic acid ranging from 5:95 to 95:5 and preferably a monomer mole ratio of glycolic acid to L-lactic acid ranging from 45:65 to 95:5. The glycolide-caprolactone copolymers include glycolide and ε-caprolactone block copolymer, e.g., Monocryl or Poliglecaprone.

Oral vaccine formulations are disclosed having microparticles sized such that at least 50% of the microparticles are less than 5 mum, preferably less than 3 mum, the microparticles containing antigen entrapped or encapsulated, such as by a solvent evaporation method, by a biodegradable polymer, such as poly (D,L-lactide-co-glycolide). Additionally, oral vaccine formulations are disclosed having nanoparticles sized such that at least 50% of the microparticles are less than 600 nm, preferably less than 500 nm, the nanoparticles containing antigen entrapped or encapsulated, such as by a coacervation method, by a biodegradable polymer, such as poly (D,L-lactide-co-glycolide). Protective vaccine formulations containing the B. pertussis antigens PTd or a combination of PTd and FHA are provided.

A family of selectively absorbable/biodegradable, fibrous composite constructs includes different combinations of biostable and absorbable/biodegradable yarns assembled as initially interdependent, load-bearing components, transitioning to exhibit independent functional properties during in vivo end-use. The family of constructs consists of two groups, one group is made of fiber-reinforced composites of high compliance, absorbable matrices of segmented polyaxial copolyesters reinforced with multifilament yarn constructs, which are combinations of ultrahigh molecular weight polyethylene fibers and at least one absorbable/biodegradable fiber selected from silk fibers and multifilament yarns made from linear segmented, l-lactide copolyesters and poly (3-hydroxyalkanoates, are useful in orthopedic, maxillofacial, urological, vascular, hernial repair and tissue engineering applications. The second group is made of coated and uncoated, warp-knitted mesh constructs for use in hernial, vascular, and urological tissue repair and tissue engineering.

The present invention is directed to crystalline copolymers of l-lactide and a minor portion of a cyclic monomer, preferably epsi-caprolactone or trimethylene carbonate or both. The present copolymers have a melting temperature of at least 150° C. and a crystallinity of at least 25%. Preferred are high molecular weight copolymers having an inherent viscosity of at least 1.4 dl/g. A variety of surgical constructs may be formed from the present copolymers. Surgical sutures made of mono- or multifilament yarns of the present copolymers will bioabsorb in less than three years and will maintain at least 50% of their initial strength three weeks post-operatively.

A medicine eluted cardiovascular frame is composed of expandible support and the medicine coated biodegradable layer coated on the said frame. The said biodegradable material contains one of the homopolymer and copolymer of glycollide, L-lactide or epsilon-caprolactone, and the copolymer of multi-group amino acids. The medicine can resist the cardiovascular narrowness. The process for preparing the said support includes such steps as preparing the said expandible support, immersing it in the mixture of the said medicine, biodegradable material and solvent, and drying. It can prevent thrombosis.

A surgical fastener configured to close an opening in tissue is provided. The surgical fastener includes a base defining a central axis at least one pair of legs extending from the base. Each of the legs includes a base portion and a tissue engaging portion. When in a first position, each of the tissue engaging portions is arranged to define an insertion direction and when in a second position, each of the tissue engaging portions extends inward towards the central axis. The surgical fastener is at least partially formed from a shape memory material including a combination of Polydioxanone and Poly(L-lactide) or a combination of Trimethylene Carbonate and Poly(L-lactide). The pair of legs are configured to move from the first position to the second position upon activation of the shape memory material.

The present invention is directed to crystalline copolymers of l-lactide and a minor portion of a cyclic monomer, preferably epsi-caprolactone or trimethylene carbonate or both. The present copolymers have a melting temperature of at least 150° C. and a crystallinity of at least 20%. Preferred are high molecular weight copolymers having an inherent viscosity of at least 1.1 dl/g. A variety of surgical constructs may be formed from the present copolymers. Disclosed are coated surgical constructs including sutures made of multifilament yarns of the present copolymers and coated with nitrogenous copolyesters which will bioabsorb in less than three years and will maintain at least 50% of their initial strength three weeks post-operatively.

The bioabsorbable polymers and compositions of the present invention may be formed into medical devices such as stents that can be crimped onto a catheter system for delivery into a blood vessel. The properties of the bioabsorbable polymers allow for both crimping and expansion of the stent. The crystal properties of the bioabsorbable polymers may change during crimping and/or expansion allowing for improved mechanical properties such as tensile strength and slower degradation kinetics. Typically, bioabsorbable polymers comprise aliphatic polyesters based on lactide backbone such as poly L-lactide, poly D-lactide, poly D,L-lactide, mesolactide, glycolides, lactones, as homopolymers or copolymers, as well as formed in copolymer moieties with co-monomers such as, trimethylene carbonate (TMC) or ε-caprolactone (ECL).

A filament bundle for degrading cigarette comprises raw materials including any one of the follows: poly(l-lactide) with crystallization accelerating agent, poly(r-lactide) with crystallization accelerating agent, and mixture of poly(l-lactide) and poly(r-lactide) with crystallization accelerating agent. The preparation method comprises the following steps: (1) drying and crystallizing at 60-120 DEG C for 10-24 hours; (2) fusing spinning at 60-120 DEG C to get protogenetic filament bundles for 10-24 hours; (3) stretching and controlling to the stretching time to be 1.5 to 3 and the trunk density of the filament bundles to be 3.0-5.0ktex; (4) crimping by a crimping machine at 40-70 DEG C, and controlling the curving number to be 18-28/25mm; and (5) baking for thermoforming at 60-100 DEG C within 10 min. The filament boundle is opened and cemented to produce a filter stick with the curing time within 50min.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

Methods and compositions for use in tissue volume replacement are provided. The present invention comprises compositions comprising a combination of materials, comprising preferably a solid polymer particle phase and a gel phase, and also comprises single phase compositions. More particularly, preferred embodiments comprise a solid polymer particle phase made of materials comprising Gore-Tex (micronized e-PTFE), PDS II (polydioxanone, a monofilament), NUROLON (a long chain aliphatic polymer Nylon 6 or Nylon 6,6) ETHILON (a long chain aliphatic polymer Nylon 6 and Nylon 6,6), PROLENE (Polypropylene, isotactic crystalline stereoisomer of polypropylene, a synthetic linear polyolefin.), VICRYL (copolymer made from 90% glycolide and 10% L-lactide), silk, MONACRYL (poly ε-caprolactone.), polylactide, polyglycolide, poly lactide-co-glycolide, and BIOPOL (polyhydroxyvalerate), MEDPOR (biocompatible (micronized) polyethylene), BIOGLASS (bioactive glass particulate), NOVABONE and NOVABONE-CM, and the gel phase comprises polyvinylpyrrolidone (PVP). Preferred single phase compositions comprise PVP. Methods of the present invention comprising injection of such compositions for tissue augmentation.

The invention discloses a method for continuously refining L-lactide from crude L-lactide, which comprises the following steps of: firstly, performing at least once lightness removal to the crude L-lactide by using a lightness-removing column, sending melted crude L-lactide into the middle of the lightness-removing column, refluxing and separating as well as distilling the crude L-lactide in the lightness-removing column, condensing vapor distillate at the upper end of the lightness-removing column for removing water, L-lactate and meso-lactide; secondly, enabling column bottom liquid to enter a reboiler for vaporization and then enter into the column, performing at least once rectification to the left column bottom liquid through a treating column after cooling, wherein the lower end of the lightness-removing column mainly has high-boiling point distillate liquid comprising the L-lactide and lactate oligomer; and when in rectification, refluxing and separating the column bottom liquid of the lightness-removing column to obtain a refined L-lactide; refining column bottom flow to obtain concentrated lactate oligomer. The L-lactide purified by the method can be directly used in the polymerization of poly L-lactate, thereby lowering the purifying cost of the L-lactide, increasing the yield, and being environmental friendly without organic solvents.

The present invention is directed toward an absorbable crystalline segmented copolymer comprising a polyalkylene succinate segment end-grafted in a single-step with a mixture of monomers comprising caprolactone, l-lactide, and/or glycolide. The present invention is also directed toward an absorbable crystalline segmented copolymer arising from a trihydroxy compound that is reacted in a single-step with a mixture of monomer comprising ε-caprolactone, l-lactide, and/or glycolide to produce monocentric polyaxial polymers.

Methods of fabricating a low crystallinity polymer tube for polymers subject to strain-induced crystallization. The low crystallinity tube may be further processed to make an implantable medical device.

The invention discloses a carboxymethyl cellulose grafted polylactic acid amphiphilic polymer, as well as a preparation method and an application thereof. The method comprises the following steps: dissolving carboxymethyl cellulose in an ionic liquid to form a homogeneous solution; adding grafting monomers, namely L-lactide monomers and a catalyst, namely stannous octoate into the homogeneous solution; controlling the temperature at 100 DEG C-130 DEG C, performing magnetic stirring, reacting for 18-24 hours in the presence of nitrogen, stopping the reaction and reducing the temperature of a system to room temperature; pouring the reaction system into ethanol to produce a precipitate, filtering and separating the precipitate, and washing with anhydrous ethanol; performing extraction on an obtained product in acetone, and performing vacuum drying to get the purified carboxymethyl cellulose grafted polylactic acid amphiphilic polymer. A dialysis method is utilized for forming self-assembled nanosphere-like micelles of the carboxymethyl cellulose grafted polylactic acid amphiphilic polymer, the particle size is 30-150nm, the critical micelle concentration is 0.01-0.1g/L and the anti-dilution stability is good.

The invention discloses a ureteral stent tube made of a degradable material. The stent tube is a double-layer compound tube, the inner layer is constituted by a L-lactide/epsilon-caprolactone copolymer (PLLCA) elastomer material, and the weight average molecular weight of an L-lactide/epsilon-caprolactone copolymer is 0.1-0.8 million, wherein an epsilon-caprolactone unit accounts for 15%-25% in the copolymer, an L-lactide unit accounts for 75%-85%, and a layer of poly-1,4-dioxanone (PPDO) is uniformly covered on the outer layer of the ureteral stent tube. The viscosity average molecular weight is 0.1-0.5 million. The ureteral stent tube has the advantages of being good in biocompatibility, being capable of realizing self-degradation, being capable of being degraded and excreted from a body without drawing the tube, and reducing suffering and economic burden of a patient.

The invention relates to a biodegradable hydrogel controlled release preparation and a preparation and an application thereof, belonging to the technology field of medicines. The preparation method comprises the steps of: synthesizing poly(lactic acid)-polyethylene glycol-poly(lactic acid) (PLA-PEG-PLA) triblock copolymer by inducing L-lactide and D-lactide to respectively conduct ring-expansion polymerization by using zinc powder, zinc lactate or stannous octoate as catalyst and polyethylene glycol (PEG) 2,000-20,000; respectively dissolving poly-L-lactic acid-polyethylene glycol-poly-L-lactic acid and poly-D-lactic acid-polyethylene glycol-poly-D-lactic acid in water to obtain solutions with concentration of 0.05-0.5g/mL, swelling, mixing, and allowing gelatinization under constant temperature to obtain PLA-PEG-PLA triblock copolymer hydrogel for injection by complexing reaction. The hydrogel has good biological compatibility and biodegradability, can be used for embedding water-soluble drugs, and is an ideal drug controlled release carrier.

The present invention discloses one kind of medical ureter rack tube made of absorbable material. The absorbable material is epsilon-caprolactone-lactide copolymer or the copolymer of epsilon-caprolactone and lactide and/or diglycolide of molecular weight 50-800 KD, where epsilon-caprolactone accounts for 10-80 wt% of the copolymer and the lactide is DL-lactide or L-lactide. The absorbable material for ureter rack tube has excellent biocompatibility, can degrade automatically and may be exhausted out after degrading with less pain and burden.